Avita Medical (AVMXY) 1.2640 $AVMXY
Avita Medical Announces First Patient Enrollment in US Pivotal Study of ReCell(R) for the Treatment of Burns
Marketwired - Wed Jan 28, 4:30AM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the first patient has been enrolled in the Company's Pivotal Phase III burn trial for ReCell(R).
AVH: 12.33 (+0.06)
UPDATE - Avita Medical Provides NICE Guidance Recommendation Update
Marketwired - Wed Nov 12, 4:04PM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the United Kingdom's National Institute for Health and Care Excellence (NICE) has issued guidance around the use of ReCell(R) Spray-on Skin(R) for the treatment of skin loss, scarring and depigmentation after a burn injury. While NICE commented that ReCell demonstrates potential to improve healing of acute burns, more evidence is required before a formal recommendation can be granted.
AVH: 12.33 (+0.06)
Avita Medical Provides NICE Guidance Recommendation Update
Marketwired - Wed Nov 12, 12:10PM CST
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the United Kingdom's National Institute for Health and Care Excellence (NICE) has issued guidance around the use of ReCell(R) Spray-on Skin(R) for the treatment of skin loss, scarring and depigmentation after a burn injury. While NICE commented that ReCell demonstrates potential to improve healing of acute burns, more evidence is required before a formal recommendation can be granted. The Company is continuing collaboration with the Medical Technologies Evaluation Programme at NICE toward further development of the evidence base.
AVH: 12.33 (+0.06)
Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive
Marketwired - Tue Nov 11, 4:30AM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has received an Australian R&D Tax Incentive payment of $1.4M for the financial year ending 30 June 2014.
AVH: 12.33 (+0.06)
Avita Medical Secures US FDA Approval to Modify ReCell(R) Clinical Burns Trial
Marketwire - Tue Sep 16, 11:25AM CDT
Highlights
AVH: 12.33 (+0.06)
Scar Treatment Market to 2018: Gels, Creams, Oils and Sprays & Invasive Surgical Treatment, Laser Treatment, Elastic Wraps and Gel Sheets
M2 - Wed Jul 16, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c4tlhl/global_scar) has announced the addition of the "Global Scar Treatment Market 2014-2018" report to their offering. Scar treatment products are applied on a scar to treat, heal, and conceal the scar. Products such as gels, creams, oils, and sprays are available as OTC products or are prescribed to treat scars. They are an alternative to invasive surgical treatment, laser treatment, elastic wraps, and gel sheets. Scar treatment application products are easy to use and cost-effective in comparison with invasive treatments. The Global Scar Treatment market can be divided into three segments: Burn Scars, Post-surgical Scars Other than Burn Scars, and Others. Burn scars, also known as hypertrophic scars, stay within the area of the original burn. The treatment of post-surgical scars varies with the degree of scarring. The treatment removes the scars caused by minor surgeries such as appendectomy or Caesarean section scars. Some scars can be hypersensitive and decrease ability to move. The Others segment includes scar treatment for aesthetic reasons such as the reduction in the appearance of acne scars. The Global Scar Treatment market is driven by many factors, one of which is an increase in appearance-consciousness among consumers. Scars leave an undesirable mark on the skin, which has a profound impact on the physical and mental well-being of a person. There has been an increase in the desire to maintain flawless skin, which is leading to an increase in the number of personal care and pharmaceutical scar treatment products. The report states that the risk of side effects is one of the major challenges. Scar treatment products may contain harmful chemicals that could cause side effects. Therefore, consumers are more concerned about the ingredients in these products. Some vendors are unable to meet the expectations of customers when it comes to safety standards. Key Vendors - CCA Industries Inc. - Merz Pharmaceuticals GmbH & Co. KGaA - Oculus Innovative Sciences Inc. - Pacific World Corp. Other Prominent Vendors - Avita Medical Ltd. - Enaltus LLC - Quantum Inc. - Revitol Corp. - Scarguard Labs LLC - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/c4...lobal_scar
CAW: 3.47 (+0.03), OCLS: 0.80 (-0.01), VRX.TO: 207.95 (-1.47)
Avita Medical Announces First Patient Enrollment in US Pivotal Study of ReCell(R) for the Treatment of Burns
Marketwired - Wed Jan 28, 4:30AM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the first patient has been enrolled in the Company's Pivotal Phase III burn trial for ReCell(R).
AVH: 12.33 (+0.06)
UPDATE - Avita Medical Provides NICE Guidance Recommendation Update
Marketwired - Wed Nov 12, 4:04PM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the United Kingdom's National Institute for Health and Care Excellence (NICE) has issued guidance around the use of ReCell(R) Spray-on Skin(R) for the treatment of skin loss, scarring and depigmentation after a burn injury. While NICE commented that ReCell demonstrates potential to improve healing of acute burns, more evidence is required before a formal recommendation can be granted.
AVH: 12.33 (+0.06)
Avita Medical Provides NICE Guidance Recommendation Update
Marketwired - Wed Nov 12, 12:10PM CST
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the United Kingdom's National Institute for Health and Care Excellence (NICE) has issued guidance around the use of ReCell(R) Spray-on Skin(R) for the treatment of skin loss, scarring and depigmentation after a burn injury. While NICE commented that ReCell demonstrates potential to improve healing of acute burns, more evidence is required before a formal recommendation can be granted. The Company is continuing collaboration with the Medical Technologies Evaluation Programme at NICE toward further development of the evidence base.
AVH: 12.33 (+0.06)
Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive
Marketwired - Tue Nov 11, 4:30AM CST
Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has received an Australian R&D Tax Incentive payment of $1.4M for the financial year ending 30 June 2014.
AVH: 12.33 (+0.06)
Avita Medical Secures US FDA Approval to Modify ReCell(R) Clinical Burns Trial
Marketwire - Tue Sep 16, 11:25AM CDT
Highlights
AVH: 12.33 (+0.06)
Scar Treatment Market to 2018: Gels, Creams, Oils and Sprays & Invasive Surgical Treatment, Laser Treatment, Elastic Wraps and Gel Sheets
M2 - Wed Jul 16, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c4tlhl/global_scar) has announced the addition of the "Global Scar Treatment Market 2014-2018" report to their offering. Scar treatment products are applied on a scar to treat, heal, and conceal the scar. Products such as gels, creams, oils, and sprays are available as OTC products or are prescribed to treat scars. They are an alternative to invasive surgical treatment, laser treatment, elastic wraps, and gel sheets. Scar treatment application products are easy to use and cost-effective in comparison with invasive treatments. The Global Scar Treatment market can be divided into three segments: Burn Scars, Post-surgical Scars Other than Burn Scars, and Others. Burn scars, also known as hypertrophic scars, stay within the area of the original burn. The treatment of post-surgical scars varies with the degree of scarring. The treatment removes the scars caused by minor surgeries such as appendectomy or Caesarean section scars. Some scars can be hypersensitive and decrease ability to move. The Others segment includes scar treatment for aesthetic reasons such as the reduction in the appearance of acne scars. The Global Scar Treatment market is driven by many factors, one of which is an increase in appearance-consciousness among consumers. Scars leave an undesirable mark on the skin, which has a profound impact on the physical and mental well-being of a person. There has been an increase in the desire to maintain flawless skin, which is leading to an increase in the number of personal care and pharmaceutical scar treatment products. The report states that the risk of side effects is one of the major challenges. Scar treatment products may contain harmful chemicals that could cause side effects. Therefore, consumers are more concerned about the ingredients in these products. Some vendors are unable to meet the expectations of customers when it comes to safety standards. Key Vendors - CCA Industries Inc. - Merz Pharmaceuticals GmbH & Co. KGaA - Oculus Innovative Sciences Inc. - Pacific World Corp. Other Prominent Vendors - Avita Medical Ltd. - Enaltus LLC - Quantum Inc. - Revitol Corp. - Scarguard Labs LLC - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/c4...lobal_scar
CAW: 3.47 (+0.03), OCLS: 0.80 (-0.01), VRX.TO: 207.95 (-1.47)
